Namilumab - Amgen/Izana Bioscience/Takeda
Alternative Names: AMG 203; Amg203; IZN 101; MT-203; MT03Latest Information Update: 12 Dec 2024
At a glance
- Originator Micromet Inc
- Developer Izana Bioscience; Kinevant Sciences; Takeda Pharmaceuticals International GmbH
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ankylosing spondylitis; Sarcoidosis
- No development reported COVID 2019 infections
- Discontinued Plaque psoriasis; Pulmonary sarcoidosis; Rheumatoid arthritis
Most Recent Events
- 12 Dec 2024 Kinevant Sciences terminates phase II RESOLVE-Lung trial in Pulmonary sarcoidosis in Belgium, France, Germany, Netherlands, Turkey, United Kingdom and the US (SC) (NCT05314517) (EudraCT-2021-004794-31)
- 03 Dec 2024 Efficacy and adverse events data from the RESOLVE-Lung phase II trial in Sarcoidosis released by Kinevant Sciences
- 03 Dec 2024 Discontinued - Phase-II for Pulmonary sarcoidosis in Belgium, France, Germany, Netherlands, Turkey, United Kingdom, USA (SC)